

Final Report



CONFIDENTIAL

A study to assess the virucidal activity of a test article against Avian Influenza A NIBRG-14 (H5N1) virus

Report Author: Miss Charlotte Chan
Retroscreen Virology Ltd.
Center for Infectious Diseases
Bart's & The London
Queen Mary's School of Medicine & Dentistry
Medical Sciences Building
327 Mile End Road
London E1 4NS

Sponsor: Mr. Jerry Burke
Skinvisible Pharmaceuticals, Inc.
Suite 10
Las Vegas
Nevada 89120
U. S. A.

Study No: SKV-PCF-001

RESULTS

MDCK cell survivability

The survivability of MDCK cells after treatment for ~1 hour with Invisicare® was >100%* (see section 8.3 for details of the assay). The measurement obtained was unusually higher than the untreated cell control and may have been a result of the test article (i.e. the test article may promote cell growth).

Reduction in NIBRG-14 (H5N1) virus titre

The results of the virucidal assay (see section 8.4 for details) are indicated in Table 1 below.

Table 1 The reduction in virus titre of NIBRG-14 (H5N1) virus after treatment with Invisicare® for different incubation times and with the positive control article

Treatment	Virus titre recovered (log ₁₀ TCID ₅₀ /ml)		Reduction in virus titre	
	Virus control	Test article	(-log ₁₀ TCID ₅₀ /ml)	(%)
Invisicare®/15 seconds	4.50	2.50	2.00	99.00
Invisicare®/30 seconds	4.50	2.50	2.00	99.00
Invisicare®/1 minute	5.00	2.75	2.25	99.44
Invisicare®/5 minutes	4.75	2.50	2.25	99.44
Citrate buffer (pH3.5)	5.25	<1.50	>3.75	>99.98

CONCLUSION

The results of the cytotoxicity assay are indicative of the test article being non-toxic to the MDCK cell line.

At all time points tested, the test article reduced the virus titre by at least 2 -log₁₀ TCID₅₀/ml (99%). The higher test article incubation time points (1 and 5 minutes) were observed to reduce the virus titre by 0.25 log₁₀ TCID₅₀/ml more than the lower time points (15 and 30 seconds).